Today Is Cancer-Focused Deals Day: Johnson & Johnson Scoops Up Ambrx Biopharma As Merck Boosts Cancer Portfolio With Harpoon Deal – Ambrx Biopharma (NASDAQ:AMAM), Johnson & Johnson (NYSE:JNJ)
Monday, Johnson & Johnson JNJ has agreed to acquire Ambrx Biopharma Inc AMAM in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired.…